Buprenorphine PR is under clinical development by Camurus and currently in Pre-Registration for Opium (Opioid) Addiction. According to GlobalData, Pre-Registration drugs for Opium (Opioid) Addiction have an 86% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how Buprenorphine PR’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Buprenorphine PR overview

Buprenorphine (Buvidal) is a semi-synthetic oripavine derivative, acts as an opioid analgesic agent. It is formulated as prolonged release solution for subcutaneous route of administration. Buvidal is indicated for the treatment of opioid dependence within a framework of medical, social and psychological treatment in adults and adolescents of 16 years and above and for moderate to severe opioid use disorder (OUD) in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine.

Buprenorphine (CAM-2038) is under development for the treatment of moderate to severe chronic pain, moderate to severe chronic back pain (chronic low back pain), opium (opioid addiction) and opioid use disorder. It is administered through subcutaneous and sublingual routes as a solution. The drug candidate is developed based on FluidCrystal injectable depot technology.

Camurus overview

Camurus, a subsidiary of Sandberg Development AB, is a pharmaceutical company. It carries out development and commercialization of treatments for the patients suffering from chronic diseases. The company’s major products include CAM2038 to treat chronic pain; CAM2029 to treat acromegaly, GEP-NET and PLD; CAM4072 to treat genetic obesity disorders; CAM2032 to treat Prostate cancer; CAM2043 to treat pulmonary arterial hypertension and raynaud’s phenomenon; CAM4071 to treat endocrine disorders; buvidal drug candidates. It sells drugs under the brand name of Episil, FluidCrystal. The company has developmental and commercial collaborations with biotechnology and pharmaceutical companies for product development. Camurus is headquartered in Lund, Sweden.

For a complete picture of Buprenorphine PR’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.